Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -221.81% | -84.76% | 52.90% | -9.74% | 26.85% |
| Total Depreciation and Amortization | 0.64% | 1.29% | 26.09% | 2.51% | 1.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.34% | 163.39% | -1,779.61% | -108.64% | 10.63% |
| Change in Net Operating Assets | 452.75% | 90.78% | -39.52% | -22.14% | 30.20% |
| Cash from Operations | -5.30% | 332.16% | -275.85% | -81.61% | 195.36% |
| Capital Expenditure | 41.57% | -45.90% | 39.60% | -320.83% | 82.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | 100.00% | 99.39% | -- | -- | -- |
| Cash from Investing | 43.48% | -101.75% | 5,293.07% | -320.83% | 82.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 50.00% | -33.33% |
| Issuance of Common Stock | -29.50% | 150.45% | -51.32% | 50.00% | -95.95% |
| Repurchase of Common Stock | 100.00% | -17.54% | -837.85% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 14.55% | -- | 100.00% |
| Cash from Financing | 107.87% | -8.69% | -2,762.50% | -154.05% | -96.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,349.74% | -89.15% | 253.61% | -86.95% | -21.45% |